Prasterone - Genelabs

Drug Profile

Prasterone - Genelabs

Alternative Names: Anastar; Aslera; Dehydroepiandrosterone - Genelabs; DHEA - Genelabs; E 10; GL 701; Prestara

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Genelabs Technologies
  • Class Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic lupus erythematosus
  • New Molecular Entity No

Highest Development Phases

  • No development reported Systemic lupus erythematosus

Most Recent Events

  • 05 Aug 2010 No development reported - Phase-III for Systemic lupus erythematosus in USA (PO)
  • 05 Aug 2010 No development reported - Preregistration for Systemic lupus erythematosus in Europe (PO)
  • 07 Jan 2009 Genelabs Technologies has been acquired by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top